|Free Dividend Report|
|Stock Splits Calendar|
|MNKD Stock Split History|
|Preferred Stock Newsletter|
|MNKD Options Chain|
|MNKD Message Board|
MannKind (MNKD) has 1 split in our MNKD split history database. The split for MNKD took place on March 03, 2017. This was a 1 for 5 reverse split, meaning for each 5 shares of MNKD owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.
When a company such as MannKind conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MNKD split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MannKind shares, starting with a $10,000 purchase of MNKD, presented on a split-history-adjusted basis factoring in the complete MNKD split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-12.50%|
|MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. Co.'s primary product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Co. collaborates with United Therapeutics to develop an inhaled formulation of treprostinil known as Tyvaso DPI. According to our MNKD split history records, MannKind has had 1 split.|
|MNKD Split History Table|
|03/03/2017||1 for 5|
|Healthcare Stock Splits|
|MNKD is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: MNKD shares outstanding history